Download PDF
Dtsch Med Wochenschr 2018; 143(01): 46-51
DOI: 10.1055/s-0043-124004
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Maligne B-Zell-Lymphome: Fortschritte in der Therapie des follikulären Lymphoms und des Mantelzell-Lymphoms[*]

Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma
Christian Buske
,
Martin Dreyling
Further Information

Publication History

Publication Date:
09 January 2018 (online)

Also available at
    Permissions and Reprints

Prof. Dr. Wolfgang Hiddemann hat seit der Gründung der „Deutschen Studiengruppen für niedrigmaligne Lymphome“ (www.glsg.de) im Jahr 1988 die Lymphomforschung national und international maßgeblich beeinflusst und neue Standards in der Therapie der Lymphome gesetzt. Der vorliegende, ihm gewidmete Beitrag, fasst die Fortschritte auf dem Gebiet der malignen B-Zell-Lymphome am Beispiel des follikulären Lymphoms (FL) und des Mantelzell-Lymphoms (MZL) zusammen.

Schlüsselwörter

B-Zell-Lymphome - follikuläres Lymphom - Mantelzell-Lymphom - Rituximab

Key words

B-cell lymphoma - follicular lymphoma - mantle-cell lymphoma - Rituximab

* Gewidmet Herrn Prof. Dr. med. Wolfgang Hiddemann anlässlich seiner Verabschiedung als DMW-Herausgeber.


 

  • Literatur

  • 1 Solal-Celigny P, Roy P, Colombat P. et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265
    CrossrefPubMedGoogle Scholar
  • 2 Buske C, Hoster E, Dreyling M. et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508
    CrossrefPubMedGoogle Scholar
  • 3 Federico M, Bellei M, Marcheselli L. et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562
    CrossrefPubMedGoogle Scholar
  • 4 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
    CrossrefPubMedGoogle Scholar
  • 5 Jurinovic V, Kridel R, Staiger AM. et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 2016; 128: 1112-1120
    CrossrefPubMedGoogle Scholar
  • 6 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
    CrossrefPubMedGoogle Scholar
  • 7 Flinn IW, van der Jagt R, Kahl BS. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952
    CrossrefPubMedGoogle Scholar
  • 8 Marcus R, Davies A, Ando K. et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med 2017; 377: 1331-1344
    CrossrefPubMedGoogle Scholar
  • 9 Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia 2014; 28: 1388-1395
    CrossrefPubMedGoogle Scholar
  • 10 Morton LM, Wang SS, Devesa SS. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265-276
    CrossrefPubMedGoogle Scholar
  • 11 Fowler NH, Davis RE, Rawal S. et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311-1318
    CrossrefPubMedGoogle Scholar
  • 12 Gopal AK, Kahl BS, de Vos S. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018
    CrossrefPubMedGoogle Scholar
  • 13 Advani RH, Buggy JJ, Sharman JP. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94
    PubMedGoogle Scholar
  • 14 Lesokhin AM, Ansell SM, Armand P. et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol 2016; 34: 2698-2704
    CrossrefPubMedGoogle Scholar
  • 15 Davids MS, Roberts AW, Seymour JF. et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 2017; 35: 826-833
    CrossrefPubMedGoogle Scholar
  • 16 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
    CrossrefPubMedGoogle Scholar
  • 17 Dreyling M, Campo E, Hermine O. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (04) iv62-iv71
    CrossrefPubMedGoogle Scholar
  • 18 Hoster E, Rosenwald A, Berger F. et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016; 34: 1386-1394
    CrossrefPubMedGoogle Scholar
  • 19 Schulz H, Bohlius JF, Trelle S. et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706-714
    CrossrefPubMedGoogle Scholar
  • 20 Kluin-Nelemans HC, Hoster E, Hermine O. et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531
    CrossrefPubMedGoogle Scholar
  • 21 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphoma. Lancet 2013; 381: 1203-1210
    CrossrefPubMedGoogle Scholar
  • 22 Hermine O, Hoster E, Walewski J. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger). Lancet 2016; 388: 565-575
    CrossrefPubMedGoogle Scholar
  • 23 Dreyling M, Lenz G, Hoster E. et al. Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma. Blood 2005; 105: 2677-2684
    CrossrefPubMedGoogle Scholar
  • 24 Zoellner AK, Fritsch S, Prevalsek D. et al. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant 2015; 50: 679-684
    CrossrefPubMedGoogle Scholar
  • 25 Dreyling M, Jurczak W, Jerkeman M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. Lancet 2016; 387: 770-778
    CrossrefPubMedGoogle Scholar
  • 26 Trneny M, Lamy T, Walewski J. et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT). Lancet Oncol 2016; 17: 319-331
    CrossrefPubMedGoogle Scholar
  • 27 Hess G, Herbrecht R, Romaguera J. et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829
    CrossrefPubMedGoogle Scholar
  • 28 Robak T, Huang H, Jin J. et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944-953
    CrossrefPubMedGoogle Scholar
  • 29 Hiddemann W, Kneba M, Dreyling M. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106 (12) 3725-3732
    CrossrefPubMedGoogle Scholar